Diagnostic accuracy of isolated or combined sCD141, MMP-3, IL-6 and CXCL9 in the whole study population and subclinical GCA
| Patients with PMR versus GCA | PMR versus subclinical GCA | |||||||
| Cut-off | AUC | Se (95% CI) | Spe (95% CI) | Cut-off | AUC | Se (95% CI) | Spe (95% CI) | |
| sCD141 | >6.1 ng/mL | 0.70 | 65.5 (47.3; 80.1) | 75.5 (61.3; 85.7) | >6.9 ng/mL | 0.81 | 75.0 (40.9; 95.5) | 86.7 (73.8; 93.7) |
| MMP-3 | <14.7 ng/mL | 0.67 | 34.4 (19.9; 52.6) | 100 (92.1; 100) | <14.7 ng/mL | 0.56 | 37.5 (13.6; 69.4) | 100 (92.1; 100) |
| IL-6 | <11.3 pg/mL | 0.69 | 58.6 (40.7; 74.4) | 82.2 (68.6; 90.7) | <12.2 pg/mL | 0.57 | 50.0 (21.5; 78.4) | 77.8 (63.3; 87.4) |
| CXCL9 | >406.7 pg/mL | 0.70 | 79.3 (61.6; 90.1) | 60 (45.4; 72.9) | >871.1 pg/mL | 0.56 | 37.5 (13.6; 69.4) | 88.0 (76.2; 95.1) |
| MMP-3/sCD141 ratio | <5.3 | 0.79 | 79.3 (61.6; 90.1) | 71.1 (56.6; 82.2) | <5.1 | 0.77 | 75.0 (40.9; 95.5) | 73.3 (58.9; 84.0) |
| CXCL9/IL-6 ratio | >32.8 | 0.76 | 79.3 (61.6; 90.1) | 73.3 (58.9; 84.0) | >32.8 | 0.59 | 62.5 (30.5; 86.3) | 73.3 (58.9; 84.0) |
AUC, area under the curve; GCA, giant cell arteritis; IL-6, interleukin-6; MMP, matrix metalloproteinase; PMR, polymyalgia rheumatica; Se, sensitivity; Spe, specificity.